Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data from UK Biobank

Quantifying Importance of Major Risk Factors for Coronary Heart Disease

(2019) Michael J. Pencina et al.   CIRCULATION

UK Biobank, big data, and the consequences of non-representativeness

(2019) Katherine M Keyes et al.   LANCET

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

(2018) Michel R. Langlois et al.   CLINICAL CHEMISTRY

Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice

(2018) Stella Trompet et al.   CURRENT OPINION IN LIPIDOLOGY

Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records

(2017) Mika Kivimäki et al.   EPIDEMIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

(2017) Julia Hippisley-Cox et al.   BMJ-British Medical Journal

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

(2017) Julia Hippisley-Cox et al.   BMJ-British Medical Journal

Association of Body Mass Index With Cardiometabolic Disease in the UK Biobank

(2017) Donald M. Lyall et al.   JAMA Cardiology

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   ATHEROSCLEROSIS

An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB

(2016) Allan D. Sniderman et al.   Journal of Clinical Lipidology

Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein CholesterolCLINICAL PERSPECTIVE

(2015) Mohamed B. Elshazly et al.   CIRCULATION

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

(2015) Terry A. Jacobson et al.   Journal of Clinical Lipidology

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

(2015) Cathie Sudlow et al.   PLOS MEDICINE

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

(2013) David C. Goff et al.   CIRCULATION

Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events

(2013) Samia Mora et al.   CIRCULATION

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

(2012) S. Matthijs Boekholdt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

What makes UK Biobank special?

(2012) Rory Collins   LANCET

Non–high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training

(2011) Smita I. Negi et al.   Journal of Clinical Lipidology

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

(2011) Vimal Ramjee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipid parameters for measuring risk of cardiovascular disease

(2011) Benoit J. Arsenault et al.   Nature Reviews Cardiology

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

(2010) Michael J. Pencina et al.   STATISTICS IN MEDICINE

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

(2009) J. H. Contois et al.   CLINICAL CHEMISTRY

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine

(2008) P. Elliott et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients

(2008) Christie M. Ballantyne et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

(2008) Matthew J McQueen et al.   LANCET